Press Releases
Search by Year
-
23 Apr 2013
bioMérieux - First-Quarter 2013 Business Review
Stable sales in a persistently difficult European economy 2013 objective of 3-5% organic sales growth maintained Solid commercial negotiations underway Confirmed favorable growth prospects in emerging...
-
25 Mar 2013
Veolia Environnement and bioMérieux initiate a research partnership to develop an innovative monitoring system for drinking water quality
Paris, Lyon, March 25, 2013 – At BIOVISION, the world life sciences forum, Veolia Environnement, global leader in water services and expert in environmental services, and bioMérieux, global player in ...
-
13 Mar 2013
biomerieux-2012-financial-results
2012 performance: objectives met Sales up 6.8% at constant exchange rates €260 million in operating income before non-recurring items €134 million in free cash flow Robust international expansion, par...
-
23 Jan 2013
2012 Business Review & Investor Day
2012 Business Review Sales up 6.8% at constant exchange rates, in line with targets for the year Investor Day Innovation and commercial strategy to drive competitiveness...
-
04 Dec 2012
bioMérieux Opens a Subsidiary in Vietnam, Strengthening its Footprint in High-growth Southeast Asia
Marcy l’Etoile, France – bioMérieux, a world leader in the field of in vitro diagnostics, announces the opening of its 41st commercial subsidiary in Hanoi, Vietnam. This wholly owned company in Vietna...
-
15 Nov 2012
bioMérieux and Quanterix Sign Strategic Partnership in Ultrasensitive and Multiplex Immunoassays
Quanterix’s Simoa™ technology to be developed for diagnostic applications. bioMérieux gains exclusive rights for clinical laboratories and industrial applications. bioMérieux takes equity stake in Qua...
-
07 Nov 2012
VIDAS® 3, the New-generation VIDAS®
VIDAS® 3, the New-generation VIDAS® Presented at the JIB International Biologists Congress...
-
31 Oct 2012
Dr. Mark Miller joins bioMérieux as Chief Medical Officer
World-leading expert on infectious disease prevention and control to enhance medical value of bioMérieux’s solutions...
-
23 Oct 2012
bioMérieux - Business Review for the nine months ended September 30, 2012
Sales Up 7.5% at constant exchange rates Of which 3.2%* organic growth Confirmed strong momentum in emerging markets 28% of consolidated sales 17%* organic growth...
-
09 Oct 2012
Avis de projet de fusion bioMérieux / AES Laboratoire groupe
French version only...